Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate

Magnetic Resonance Imaging

Volumn 27, Issue 3, 2009, Pages 377-384

  Bradley, Daniel P ^a   Tessier, Jean J ^a   Lacey, Tony ^a   Scott, Marietta ^a   Jürgensmeier, Juliane M ^a   Odedra, Rajesh ^a   Mills, Jonathan ^a   Kilburn, Lyndsey ^a   Wedge, Stephen R ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Biomarker; Cediranib (RECENTIN, AZD2171); DCE MRI; Gadopentate, VEGF signaling; VEGFR 2

Indexed keywords

CEDIRANIB; GADOTERIC ACID; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; COLORECTAL CARCINOMA; CONTRAST ENHANCEMENT; CONTROLLED STUDY; GLIOMA; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; COLORECTAL NEOPLASMS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GADOLINIUM DTPA; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; QUINAZOLINES; RATS; RATS, NUDE; TREATMENT OUTCOME;

RATTUS;

EID: 61849117290     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mri.2008.07.021     Document Type: Article

References (30)

1. Folkman J., Watson K., Ingber D., and Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339 (1989) 58-61
2. Koolwijk P., Peters E., van der Vecht B., Hornig C., Weich H.A., Alitalo K., et al. Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro. Angiogenesis 4 (2001) 53-60
3. Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273 (1998) 30336-30343
4. Han H., Silverman J.F., Santucci T.S., Macherey R.S., d'Amato T.A., Tung M.Y., et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 8 (2001) 72-79
5. Baka S., Clamp A.R., and Jayson G.C. A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets 10 (2006) 867-876
6. Ho Q.T., and Kuo C.J. Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol 39 (2007) 1349-1357
7. Moreira I.S., Fernandes P.A., and Ramos M.J. Vascular endothelial growth factor (VEGF) inhibition - a critical review. Anticancer Agents Med Chem 7 (2007) 223-245
8. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Eng J Med 350 (2004) 2335-2342
9. Dvorak H.F. Discovery of vascular permeability factor (VPF). Exp Cell Res 312 (2006) 522-526
10. Bates D.O., Lodwick D., and Williams B. Vascular endothelial growth factor and microvascular permeability. Microcirculation 6 (1999) 83-96
11. O'Connor J.P., Jackson A., Parker G.J., and Jayson G.C. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96 (2007) 189-195
12. Bhujwalla Z.M., Artemov D., Natarajan K., Solaiyappan M., Kollars P., and Kristjansen P.E. Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res 9 (2003) 355-362
13. Bradley D.P., Tessier J.L., Checkley D., Kuribayashi H., Waterton J.C., Kendrew J., et al. Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol). NMR Biomed 21 (2007) 42-52
14. Gillies R.J., Raghunand N., Karczmar G.S., and Bhujwalla Z.M. MRI of the tumor microenvironment. J Magn Reson Imaging 16 (2002) 430-450
15. Li X., Huang W., Yankeelov T.E., Tudorica A., Rooney W.D., and Springer Jr. C.S. Shutter-speed analysis of contrast reagent bolus-tracking data: preliminary observations in benign and malignant breast disease. Magn Reson Med 53 (2005) 724-729
16. Yankeelov T.E., Rooney W.D., Huang W., Dyke J.P., Li X., Tudorica A., et al. Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology. NMR Biomed 18 (2005) 173-185
17. Zhou R., Pickup S., Yankeelov T.E., Springer Jr. C.S., and Glickson J.D. Simultaneous measurement of arterial input function and tumor pharmacokinetics in mice by dynamic contrast enhanced imaging: effects of transcytolemmal water exchange. Magn Reson Med 52 (2004) 248-257
18. Wedge S.R., Kendrew J., Hennequin L.F., Valentine P.J., Barry S.T., Brave S.R., et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65 (2005) 4389-4400
19. Drevs J., Siegert P., Medinger M., Mross K., Strecker R., Zirrgiebel U., et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25 (2007) 3045-3054
20. Leach M.O., Brindle K.M., Evelhoch J.L., Griffiths J.R., Horsman M.R., Jackson A., et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92 (2005) 1599-1610
21. Tofts P.S., and Kermode A.G. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17 (1991) 357-367
22. Baudelet C., and Gallez B. Effect of anesthesia on the signal intensity in tumors using BOLD-MRI: comparison with flow measurements by Laser Doppler flowmetry and oxygen measurements by luminescence-based probes. Magn Reson Imaging 22 (2004) 905-912
23. Lagarias J.C., Reeds J.A., Wright M.H., and Wright P.E. Convergence properties of the Nelder-Mead simplex method in low dimensions. SIAM Journal of Optimisation 9 (1998) 112-147
24. Tofts P.S., Brix G., Buckley D.L., Evelhoch J.L., Henderson E., Knopp M.V., et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10 (1999) 223-232
25. Checkley D., Tessier J.J., Wedge S.R., Dukes M., Kendrew J., Curry B., et al. Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts. Magn Reson Imaging 21 (2003) 475-482
26. Wedeking P., Eaton S., Covell D.G., Nair S., Tweedle M.F., and Eckelman W.C. Pharmacokinetic analysis of blood distribution of intravenously administered 153Gd-labeled Gd(DTPA)2- and 99mTc(DTPA) in rats. Magn Reson Imaging 8 (1990) 567-575
27. Bland J.M., and Altman D.G. Transforming data. BMJ 312 (1996) 770
28. Smith N.R., James N.H., Oakley I., Wainwright A., Copley C., Kendrew J., et al. Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol Cancer Ther 6 (2007) 2198-2208
29. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007) 83-95
30. Morgan B., Thomas A.L., Drevs J., Hennig J., Buchert M., Jivan A., et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21 (2003) 3955-3964